203 related articles for article (PubMed ID: 34587309)
1. Bezafibrate therapy in primary biliary cholangitis refractory to ursodeoxycholic acid: a longitudinal study of paired liver biopsies at 5 years of follow up.
Sorda JA; González Ballerga E; Barreyro FJ; Avagnina A; Carballo P; Paes de Lima A; Daruich J
Aliment Pharmacol Ther; 2021 Nov; 54(9):1202-1212. PubMed ID: 34587309
[TBL] [Abstract][Full Text] [Related]
2. Additional fibrate treatment in UDCA-refractory PBC patients.
Chung SW; Lee JH; Kim MA; Leem G; Kim SW; Chang Y; Lee HY; Yoon JS; Park JY; Lee YB; Cho EJ; Yu SJ; Kim YJ; Yoon JH
Liver Int; 2019 Sep; 39(9):1776-1785. PubMed ID: 31162879
[TBL] [Abstract][Full Text] [Related]
3. Effects of Bezafibrate on Outcome and Pruritus in Primary Biliary Cholangitis With Suboptimal Ursodeoxycholic Acid Response.
Reig A; Sesé P; Parés A
Am J Gastroenterol; 2018 Jan; 113(1):49-55. PubMed ID: 29016567
[TBL] [Abstract][Full Text] [Related]
4. IgM response is a prognostic biomarker of primary biliary cholangitis treated with ursodeoxycholic acid and bezafibrate.
Takano K; Saeki C; Oikawa T; Hidaka A; Mizuno Y; Ishida J; Takakura K; Nakano M; Torisu Y; Amano K; Ishikawa T; Zeniya M; Tsubota A; Saruta M
J Gastroenterol Hepatol; 2020 Apr; 35(4):663-672. PubMed ID: 31677185
[TBL] [Abstract][Full Text] [Related]
5. Bezafibrate treatment of primary biliary cirrhosis following incomplete response to ursodeoxycholic acid.
Hazzan R; Tur-Kaspa R
J Clin Gastroenterol; 2010; 44(5):371-3. PubMed ID: 19881358
[TBL] [Abstract][Full Text] [Related]
6. Additive improvement induced by bezafibrate in patients with primary biliary cirrhosis showing refractory response to ursodeoxycholic acid.
Takeuchi Y; Ikeda F; Fujioka S; Takaki T; Osawa T; Yasunaka T; Miyake Y; Takaki A; Iwasaki Y; Kobashi H; Yamamoto K; Itoshima T
J Gastroenterol Hepatol; 2011 Sep; 26(9):1395-401. PubMed ID: 21443659
[TBL] [Abstract][Full Text] [Related]
7. Bezafibrate treatment: a new medical approach for PBC patients?
Kanda T; Yokosuka O; Imazeki F; Saisho H
J Gastroenterol; 2003; 38(6):573-8. PubMed ID: 12825134
[TBL] [Abstract][Full Text] [Related]
8. Long-Term Fenofibrate Treatment in Primary Biliary Cholangitis Improves Biochemistry but Not the UK-PBC Risk Score.
Hegade VS; Khanna A; Walker LJ; Wong LL; Dyson JK; Jones DEJ
Dig Dis Sci; 2016 Oct; 61(10):3037-3044. PubMed ID: 27435324
[TBL] [Abstract][Full Text] [Related]
9. Biochemical responses to bezafibrate improve long-term outcome in asymptomatic patients with primary biliary cirrhosis refractory to UDCA.
Tanaka A; Hirohara J; Nakanuma Y; Tsubouchi H; Takikawa H
J Gastroenterol; 2015 Jun; 50(6):675-82. PubMed ID: 25239675
[TBL] [Abstract][Full Text] [Related]
10. Bezafibrate Improves GLOBE and UK-PBC Scores and Long-Term Outcomes in Patients With Primary Biliary Cholangitis.
Honda A; Tanaka A; Kaneko T; Komori A; Abe M; Inao M; Namisaki T; Hashimoto N; Kawata K; Takahashi A; Ninomiya M; Kang JH; Arakawa M; Yamagiwa S; Joshita S; Umemura T; Sato K; Kaneko A; Kikuchi K; Itakura J; Nomura T; Kakisaka K; Fujii H; Kawada N; Takikawa Y; Masaki T; Ohira H; Mochida S; Yoshiji H; Iimuro S; Matsuzaki Y; Takikawa H;
Hepatology; 2019 Dec; 70(6):2035-2046. PubMed ID: 30737815
[TBL] [Abstract][Full Text] [Related]
11. Association of bezafibrate with transplant-free survival in patients with primary biliary cholangitis.
Tanaka A; Hirohara J; Nakano T; Matsumoto K; Chazouillères O; Takikawa H; Hansen BE; Carrat F; Corpechot C
J Hepatol; 2021 Sep; 75(3):565-571. PubMed ID: 33882268
[TBL] [Abstract][Full Text] [Related]
12. Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid.
Honda A; Ikegami T; Nakamuta M; Miyazaki T; Iwamoto J; Hirayama T; Saito Y; Takikawa H; Imawari M; Matsuzaki Y
Hepatology; 2013 May; 57(5):1931-41. PubMed ID: 22911624
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Bezafibrate Alone or in Combination with Ursodeoxycholic Acid in Primary Biliary Cholangitis: Systematic Review and Meta-Analysis.
Khakoo NS; Sultan S; Reynolds JM; Levy C
Dig Dis Sci; 2023 Apr; 68(4):1559-1573. PubMed ID: 36180756
[TBL] [Abstract][Full Text] [Related]
14. Fenofibrate improves GLOBE and UK-PBC scores and histological features in primary biliary cholangitis.
Wang L; Sun K; Tian A; Liu Y; Zhang M; Zhou X; Han Y
Minerva Med; 2022 Dec; 113(6):974-982. PubMed ID: 33949176
[TBL] [Abstract][Full Text] [Related]
15. Fenofibrate normalizes alkaline phosphatase and improves long-term outcomes in patients with advanced primary biliary cholangitis refractory to ursodeoxycholic acid.
Ding D; Ren P; Guo G; Liu Y; Yang C; Zheng L; Jia G; Deng J; Sun R; Wang X; Zhou X; Shang Y; Han Y
Gastroenterol Hepatol; 2023 Nov; 46(9):692-701. PubMed ID: 36632973
[TBL] [Abstract][Full Text] [Related]
16. A validation study of the Ursodeoxycholic Acid Response Score in Japanese patients with primary biliary cholangitis.
Yagi M; Matsumoto K; Komori A; Abe M; Hashimoto N; Inao M; Namisaki T; Kawata K; Ninomiya M; Fujii H; Takahashi A; Kang JH; Takamura M; Arakawa M; Joshita S; Sato K; Itakura J; Nomura T; Kakisaka K; Kaneko A; Tamura Y; Miura R; Aiso M; Arizumi T; Asaoka Y; Kikuchi K; Takikawa Y; Masaki T; Umemura T; Honda A; Ohira H; Kawada N; Yoshiji H; Mochida S; Takikawa H; Tanaka A;
Liver Int; 2020 Aug; 40(8):1926-1933. PubMed ID: 32438508
[TBL] [Abstract][Full Text] [Related]
17. [Ursodeoxycholic acid combined with bezafibrate in the treatment of refractory primary biliary cholangitis: a meta-analysis].
Feng BL; Yu HH; Shen W
Zhonghua Gan Zang Bing Za Zhi; 2019 Apr; 27(4):304-311. PubMed ID: 31082343
[No Abstract] [Full Text] [Related]
18. A placebo-controlled randomised trial of budesonide for PBC following an insufficient response to UDCA.
Hirschfield GM; Beuers U; Kupcinskas L; Ott P; Bergquist A; Färkkilä M; Manns MP; Parés A; Spengler U; Stiess M; Greinwald R; Pröls M; Wendum D; Drebber U; Poupon R
J Hepatol; 2021 Feb; 74(2):321-329. PubMed ID: 32950590
[TBL] [Abstract][Full Text] [Related]
19. Clinical features and treatment outcomes of primary biliary cholangitis in a highly admixed population.
Cançado GGL; Braga MH; Ferraz MLG; Villela-Nogueira CA; Terrabuio DRB; Cançado ELR; Nardelli MJ; Faria LC; Gomes NMF; de Oliveira EMG; Rotman V; de Oliveira MB; da Cunha SMCF; Mazo DFC; Mendes LSC; Ivantes CAP; Codes L; de Almeida E Borges VF; Pace FHL; Pessoa MG; Signorelli IV; Coral GP; Bittencourt PL; Levy C; Couto CA;
Ann Hepatol; 2022; 27(1):100546. PubMed ID: 34600142
[TBL] [Abstract][Full Text] [Related]
20. A prospective randomized controlled study of long-term combination therapy using ursodeoxycholic acid and bezafibrate in patients with primary biliary cirrhosis and dyslipidemia.
Hosonuma K; Sato K; Yamazaki Y; Yanagisawa M; Hashizume H; Horiguchi N; Kakizaki S; Kusano M; Yamada M
Am J Gastroenterol; 2015 Mar; 110(3):423-31. PubMed ID: 25732417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
